Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection

We read and appreciate the report of the executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline in Kidney International.1 Direct-acting antivirals are now the standard of care for chronic hepatitis C either in the general population or in patients with chronic kidney disease. A sustained virological response rate of>95% could be achieved with novel direct-acting antivirals. We acknowledge that the statement regarding the treatment recommendations should refer to the latest American Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver (EASL) guidelines.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Letter to the Editor Source Type: research